split-banner-image

HERA

Closed

ANZ 0101/BIG 1-01/IBCSG 28-02/B016348F: HERA

BCT Study Chair:

Nicholas Wilcken

A randomised three-arm multicentre comparison of 1 year and 2 years of Herceptin, versus no Herception in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy.

international

4992

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

110

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

21

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

HERA PUBLICATIONS

2024

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.

Early Breast Cancer Trialists’ Collaborative Group. The Lancet. 2024; 4041407-18, epub 12 October 2024, E-pub

2023

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.

Hills RK, Bradle R, Braybrooke J, Gray RG, Taylor H, Denkert C, Badve SS, Kim RS, Lacroix-Triki M, Regan MM, Hayes DF, Dowsett M, Tutt ANJ, Gelber RD, Cameron DA, Bergh JCS, Swain SM, Michiels S, Loi S, Salgado R, Early Breast Cancer Trialists’ Collaborative Group & International Immuno-Oncology Biomarker Working Group. Journal of Clinical Oncology. 2023; 41(suppl 16):Oral Abstract 508, Abstract

2022

Residual Risk of Relapse: a Systematic Review and a Consensus Project on Unmet needs for HER2-positive non Metastatic Breast Cancer Patients.

Miglietta F, Pronzato P, Girardi F, Griguolo G, Guarneri V, Pappagallo G, Conte P, Periplo foundation. European Journal of Cancer. 2022; 175(S1):s57-S58, EBCC-13 Abstract 177/PB-090, Poster

2021

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 364 women in seven randomised trials.

Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Lancet Oncology. 2021; 22(8):1139-1150, Journal

2017

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. The Lancet 2017; 389(10075):1195-1205, Journal

2016

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD, HERA Study Team. Breast Cancer Research and Treatment. 2016; 155(1):127-132, Journal

LOAD MORE

Institutions